Inovio Pharmaceuticals (INO) stock forecast for 2022
Last update: September 28, 2023 (04:44)Sector: Healthcare
The share price of Inovio Pharmaceuticals, Inc. (INO) now
50/200 Day Moving Average: $0.453 / $0.921
This figure corresponds to the Average Price over the previous 50/200 days. For Inovio Pharmaceuticals stocks, the 50-day moving average is the resistance level today.
For Inovio Pharmaceuticals stocks, the 200-day moving average is the resistance level today.
Are you interested in Inovio Pharmaceuticals stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Inovio Pharmaceuticals stock price in 2022. How much will one Inovio Pharmaceuticals share be worth in 2022? Is it worth taking profit / loss on Inovio Pharmaceuticals stock now or waiting? What are analysts' forecasts for Inovio Pharmaceuticals stock?
We forecast Inovio Pharmaceuticals stock performance using neural networks based on historical data on Inovio Pharmaceuticals stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Inovio Pharmaceuticals stock prediction results are shown below and presented as a graph, table and text information.
Inovio Pharmaceuticals stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Inovio Pharmaceuticals analysts is $1.25.
Today 200 Day Moving Average is the resistance level (0.921 $).
50 Day Moving Average is the resistance level (0.453 $).
Historical and forecast chart of Inovio Pharmaceuticals stock
The chart below shows the historical price of Inovio Pharmaceuticals stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Inovio Pharmaceuticals stock price can be found in the table below.
Inovio Pharmaceuticals (INO) Forecast for 2022
Inovio Pharmaceuticals information and performance
Inovio Pharmaceuticals, Inc. a biotechnology company specializing in the discovery, development and commercialization of DNA drugs to treat, cure and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. Its SynCon immunotherapy design has the ability to disrupt the immune system’s tolerance to cancer cells and facilitate the cross-protection of strains against unrivaled and matched pathogens. The company participates in the conduct and planning of clinical trials of its DNA drugs for the treatment of HPV-associated cancers, including dysplasia of the cervix, vulva and anus; HPV-associated cancers, including cancers of the head and neck, cervix, anal canal, penis, vulva, and vagina; other HPV-associated diseases such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East respiratory syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and employees are ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., Bill & Melinda Gates Foundation, Epidemic Preparedness Innovation Coalition (EPIR), Defense Advanced Research Projects Agency (DARPA), Life Sciences GeneOne. HIV Vaccine Threat Reduction Forensic Network, Defense Consortium Medical Weapons Agency (GCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergic and Infectious Diseases, Life Science Plumb Line, Regeneron Pharmaceuticals, Roche / Genentech, University Pennsylvania, University. Walter Reed Army Research Institute and Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support the INO-4800 DNA research vaccine currently in Phase I of the COVID-19 clinical trials; and partnerships with the International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
6769 MESA RIDGE RD., SAN DIEGO, CA, US
Market capitalization of the Inovio Pharmaceuticals, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of INO shares in the company outstanding by the market price of one share.
EBITDA of Inovio Pharmaceuticals is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Inovio Pharmaceuticals price target for 2022 by month
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.